Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Medicare moots PET (positron emission tomography) for certain Alzheimer's patients

This article was originally published in Clinica

Executive Summary

The Centers for Medicare & Medicaid Services (CMS) is proposing to expand Medicare coverage of positron emission tomography (PET) to include some elderly and disabled beneficiaries suspected of having Alzheimer's disease. Use of the imaging technique would be covered for patients with a progressive symptom of dementia for at least six months, but for whom a diagnosis remains uncertain despite a thorough clinical evaluation, CMS said. Moreover, the patient must be suspected of having front-temporal dementia, and have symptoms unlike those found for Alzheimer's.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT058761

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel